UVA and MVA for OS (including Ph-like and B-other group) (N = 109)
| Parameter . | Survival . | |||||
|---|---|---|---|---|---|---|
| n . | Median, mo . | UVA . | MVA . | |||
| P . | P . | HR . | 95% CI . | |||
| Age, y | ||||||
| ≥60 | 19 | 9.2 | .001 | <.001 | 3.299 | 1.745-6.235 |
| <60 | 90 | 50.2 | ||||
| Sex | ||||||
| Female | 53 | 63.8 | .21 | — | — | — |
| Male | 56 | 34.6 | ||||
| Ethnicity (Hispanic) | ||||||
| Yes | 54 | 32.5 | .22 | — | — | — |
| No | 55 | 63.8 | ||||
| WBC, ×109/L | ||||||
| ≥30.0 | 29 | 18.8 | .007 | .017 | 1.910 | 1.117-3.266 |
| <30 | 80 | 53.7 | ||||
| Hemoglobin, g/dL | ||||||
| <10 | 75 | 37.3 | .53 | — | — | — |
| ≥10 | 34 | 38.9 | ||||
| Platelet, ×109/L | ||||||
| <100 | 91 | 29.5 | <.001 | .005 | 7.437 | 1.792-30.855 |
| ≥100 | 18 | NR | ||||
| CNS involvement at Dx | ||||||
| Yes | 14 | 28.8 | .81 | — | — | — |
| No | 95 | 38.9 | ||||
| Ph-like ALL | ||||||
| Yes | 56 | 28.9 | .006 | .030 | 1.818 | 1.056-3.128 |
| No | 53 | NR | ||||
| Treatment received | ||||||
| Hyper-CVAD | 78 | 33.1 | .24 | — | — | — |
| Augmented BFM | 31 | 48.8 | ||||
| Parameter . | Survival . | |||||
|---|---|---|---|---|---|---|
| n . | Median, mo . | UVA . | MVA . | |||
| P . | P . | HR . | 95% CI . | |||
| Age, y | ||||||
| ≥60 | 19 | 9.2 | .001 | <.001 | 3.299 | 1.745-6.235 |
| <60 | 90 | 50.2 | ||||
| Sex | ||||||
| Female | 53 | 63.8 | .21 | — | — | — |
| Male | 56 | 34.6 | ||||
| Ethnicity (Hispanic) | ||||||
| Yes | 54 | 32.5 | .22 | — | — | — |
| No | 55 | 63.8 | ||||
| WBC, ×109/L | ||||||
| ≥30.0 | 29 | 18.8 | .007 | .017 | 1.910 | 1.117-3.266 |
| <30 | 80 | 53.7 | ||||
| Hemoglobin, g/dL | ||||||
| <10 | 75 | 37.3 | .53 | — | — | — |
| ≥10 | 34 | 38.9 | ||||
| Platelet, ×109/L | ||||||
| <100 | 91 | 29.5 | <.001 | .005 | 7.437 | 1.792-30.855 |
| ≥100 | 18 | NR | ||||
| CNS involvement at Dx | ||||||
| Yes | 14 | 28.8 | .81 | — | — | — |
| No | 95 | 38.9 | ||||
| Ph-like ALL | ||||||
| Yes | 56 | 28.9 | .006 | .030 | 1.818 | 1.056-3.128 |
| No | 53 | NR | ||||
| Treatment received | ||||||
| Hyper-CVAD | 78 | 33.1 | .24 | — | — | — |
| Augmented BFM | 31 | 48.8 | ||||
CI, confidence interval; NR, not reached.